Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 2
2005 5
2006 1
2007 6
2008 15
2009 6
2010 11
2011 19
2012 20
2013 27
2014 39
2015 41
2016 32
2017 52
2018 61
2019 52
2020 21
Text availability
Article attribute
Article type
Publication date

Search Results

372 results
Results by year
Filters applied: . Clear all
Page 1
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention.
Hostalek U, Gwilt M, Hildemann S. Hostalek U, et al. Drugs. 2015 Jul;75(10):1071-94. doi: 10.1007/s40265-015-0416-8. Drugs. 2015. PMID: 26059289 Free PMC article. Review.
Lifestyle interventions aimed at inducing weight loss, pharmacologic treatments (metformin, thiazolidinediones, acarbose, basal insulin and drugs for weight loss) and bariatric surgery have all been shown to reduce the risk of progression to type 2 …
Lifestyle interventions aimed at inducing weight loss, pharmacologic treatments (metformin, thiazolidinediones, acarbose, basa …
An Online Intervention Comparing a Very Low-Carbohydrate Ketogenic Diet and Lifestyle Recommendations Versus a Plate Method Diet in Overweight Individuals With Type 2 Diabetes: A Randomized Controlled Trial.
Saslow LR, Mason AE, Kim S, Goldman V, Ploutz-Snyder R, Bayandorian H, Daubenmier J, Hecht FM, Moskowitz JT. Saslow LR, et al. J Med Internet Res. 2017 Feb 13;19(2):e36. doi: 10.2196/jmir.5806. J Med Internet Res. 2017. PMID: 28193599 Free PMC article. Clinical Trial.
BACKGROUND: Type 2 diabetes is a prevalent, chronic disease for which diet is an integral aspect of treatment. In our previous trial, we found that recommendations to follow a very low-carbohydrate ketogenic diet and to change lifestyle factors (physical activity, sleep, p …
BACKGROUND: Type 2 diabetes is a prevalent, chronic disease for which diet is an integral aspect of treatment. In our previous trial, …
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. le Roux CW, et al. Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23. Lancet. 2017. PMID: 28237263 Clinical Trial.
In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. ...Liraglutide induced greater weight loss than placebo at week 160 …
In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with predia
Dietary Interventions for the Prevention of Type 2 Diabetes in High-Risk Groups: Current State of Evidence and Future Research Needs.
Guess ND. Guess ND. Nutrients. 2018 Sep 6;10(9):1245. doi: 10.3390/nu10091245. Nutrients. 2018. PMID: 30200572 Free PMC article. Review.
There is also a need to understand the effect of foods and diets on beta-cell function, as the available evidence suggests moderate weight loss, as achieved in the diabetes prevention trials, improves insulin sensitivity but not beta-cell function. Fin …
There is also a need to understand the effect of foods and diets on beta-cell function, as the available evidence suggests moderate weigh
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. Pi-Sunyer X, et al. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892. N Engl J Med. 2015. PMID: 26132939 Free article. Clinical Trial.
BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. ...RESULTS: At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight w …
BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through li …
Global Diabetes Prevention Interventions: A Systematic Review and Network Meta-analysis of the Real-World Impact on Incidence, Weight, and Glucose.
Galaviz KI, Weber MB, Straus A, Haw JS, Narayan KMV, Ali MK. Galaviz KI, et al. Diabetes Care. 2018 Jul;41(7):1526-1534. doi: 10.2337/dc17-2222. Diabetes Care. 2018. PMID: 29934481 Free PMC article. Review.
OBJECTIVE: Understanding the real-world impacts of lifestyle modification (LSM) for diabetes prevention is imperative to inform resource allocation. ...Effectiveness/translation studies of any design testing LSM strategies, targeting high-risk populations (with p
OBJECTIVE: Understanding the real-world impacts of lifestyle modification (LSM) for diabetes prevention is imperative to infor …
PREVENT-DM Comparative Effectiveness Trial of Lifestyle Intervention and Metformin.
O'Brien MJ, Perez A, Scanlan AB, Alos VA, Whitaker RC, Foster GD, Ackermann RT, Ciolino JD, Homko C. O'Brien MJ, et al. Am J Prev Med. 2017 Jun;52(6):788-797. doi: 10.1016/j.amepre.2017.01.008. Epub 2017 Feb 22. Am J Prev Med. 2017. PMID: 28237635 Free PMC article. Clinical Trial.
INTERVENTION: The 12-month ILI was adapted from the Diabetes Prevention Program's ILI and delivered by community health workers (promotoras) over 24 sessions. ...CONCLUSIONS: In the first comparative effectiveness trial of diabetes prevention
INTERVENTION: The 12-month ILI was adapted from the Diabetes Prevention Program's ILI and delivered by community
Diabetes Nutrition Therapy: Effectiveness, Macronutrients, Eating Patterns and Weight Management.
Franz MJ. Franz MJ. Am J Med Sci. 2016 Apr;351(4):374-9. doi: 10.1016/j.amjms.2016.02.001. Am J Med Sci. 2016. PMID: 27079343 Review.
There are no ideal percentages of macronutrients or eating patterns or both that apply to all persons with diabetes. Clinical trials demonstrate the effectiveness of modest weight loss and physical activity for the prevention or delay of type 2 diab
There are no ideal percentages of macronutrients or eating patterns or both that apply to all persons with diabetes. Clinical trials …
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee Investigators. Bohula EA, et al. Lancet. 2018 Nov 24;392(10161):2269-2279. doi: 10.1016/S0140-6736(18)32328-6. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293771 Free article. Clinical Trial.
BACKGROUND: There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor agonist that suppresses appetite, has been shown to facilitate sustained weight loss in obese or overweight patients. ...At basel …
BACKGROUND: There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor ago …
Weight loss in the prevention and treatment of diabetes.
Delahanty LM. Delahanty LM. Prev Med. 2017 Nov;104:120-123. doi: 10.1016/j.ypmed.2017.07.022. Epub 2017 Jul 28. Prev Med. 2017. PMID: 28757449
The American Diabetes Association nutrition and lifestyle recommendations for prediabetes and type 2 diabetes focus on losing 7% of body weight and increasing physical activity to at least 150minperweek. This emphasis is largely based on results of the …
The American Diabetes Association nutrition and lifestyle recommendations for prediabetes and type 2 diabetes focus on …
372 results
Jump to page
Feedback